Yahoo Search Busca da Web

Resultado da Busca

  1. Há 1 dia · Cervical cancer (CC) screening in women comprises human papillomavirus ... (that is, CIN2, CIN3, adenocarcinoma in situ (AIS) and HSIL), which may be treated before they progress to invasion.

  2. Há 2 dias · In cervical cytology, the morphology overlaps with that of other tumors, so the differentiation of rhabdomyosarcoma from cervical cytological examination is very difficult. The pathologist should be familiar with these cytological features and characteristic findings from cell block examination and IHC, allowing early and accurate diagnosis of ERMS for timely treatment and avoidance of ...

  3. Há 1 dia · Abstract. Background: Adenocarcinoma in situ (AIS) of the cervix can progress to invasive adenocarcinoma. While hysterectomy is standard, conservative management may be considered for women desiring future pregnancies.

  4. Há 10 horas · This study aims to refine our understanding of the inherent heterogeneity in cervical cancer by exploring differential gene expression profiles, immune cell infiltration dynamics, and implicated signaling pathways in the two predominant histological types of cervix carcinoma, Squamous Cell Carcinoma (SCC) and Adenocarcinoma (ADC). Targeted gene expression data that were previously generated ...

  5. Há 1 dia · Squamous cell carcinoma accounts for the majority of cases, making up about 80-90% of cervical cancers. This type of cancer develops from the flat, thin cells that line the outer part of the cervix. Adenocarcinoma, on the other hand, develops from the glandular cells that line the inner part of the cervix and makes up about 10-20% of cases.

  6. Repeat pap said "atypical endocervical cells, suspicious for adenocarcinoma in situ". Had repeat colpo which showed only CIN-1 and gyn did 5 biopsies and ECC which was negative. No atypical endocervical cells. No adenocarcinoma. Referred to Gyn-Onc. Went to appt today where I had repeat Pap and ECC.

  7. Há 2 dias · Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.